Abstract LB-347: Ang-2VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival

OBJECTIVE: We aimed to enhance the efficacy of anti-VEGF therapy in glioblastoma (GBM) through additional inhibition of Angiopoietin-2 (Ang-2), a potential mediator of resistance to antiangiogenic therapy using VEGF inhibition.

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 76; no. 14_Supplement; pp. LB - 347-LB-347
Main Authors Kloepper, Jonas, Riedemann, Lars, Amoozgar, Zohreh, Seano, Giorgio, Susek, Katharina H, Yu, Veronica, Dalvie, Nisha, Amelung, Robin L, Datta, Meenal, Song, Jonathan W, Askoxylakis, Vasileios, Taylor, Jennie W, Lu-Emerson, Christine, Batista, Ana, Kirkpatrick, Nathaniel D, Jung, Keehoon, Snuderl, Matija, Muzikansky, Alona, Stubenrauch, Kay G, Krieter, Oliver, Wakimoto, Hiroaki, Xu, Lei, Munn, Lance L, Duda, Dan G, Fukumura, Dai, Batchelor, Tracy T, Jain, Rakesh K
Format Journal Article
LanguageEnglish
Published 15.07.2016
Online AccessGet full text

Cover

More Information
Summary:OBJECTIVE: We aimed to enhance the efficacy of anti-VEGF therapy in glioblastoma (GBM) through additional inhibition of Angiopoietin-2 (Ang-2), a potential mediator of resistance to antiangiogenic therapy using VEGF inhibition.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
content type line 23
ObjectType-Feature-2
ISSN:0008-5472
1538-7445
DOI:10.1158/1538-7445.AM2016-LB-347